Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity

Internal Medicine

Volumn 51, Issue 4, 2012, Pages 431-434

  Kunimasa, Kei ^a   Yoshioka, Hiroshige ^a   Iwasaku, Masahiro ^a   Nishiyama, Akihiro ^a   Korogi, Yohei ^a   Masuda, Gen ^a   Takaiwa, Takuya ^a   Ishida, Tadashi ^a  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

Erlotinib; Gefitinib; Hepatotoxicity; Non small cell lung

Indexed keywords

ERLOTINIB; GEFITINIB; URSODEOXYCHOLIC ACID;

ADENOCARCINOMA; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACKACHE; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EGFR GENE; FEMALE; GENE; GENE MUTATION; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MULTIPLE PULMONARY NODULES; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; SIDE EFFECT; THORAX RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84857189005     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6285     Document Type: Article

References (13)

1. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
3. Takeda M, Okamoto I, Fukuoka M, Nakagawa K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol 28: e273-e274, 2010.
4. Ku GY, Chopra A, Lopes Gde L Jr. Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer 70: 223-225, 2010.
5. Liu W, Markrauer FL, Qamar AA, Jänne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 5: 917-920, 2007.
6. Huang YS, An SJ, Chen ZH, Wu YL. Three cases of severe hepatic impairment caused by erlotinib. Br J Clin Pharmacol 68: 464-467, 2009.
7. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24: 1295-1304, 2006.
8. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23: 6207-6219, 2005.
9. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4: 1415-1419, 2009.
10. Togashi Y, Masago K, Mishima M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 5: 950-955, 2010.
11. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 354: 731-739, 2006.
12. Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34: 420-426, 2006.
13. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13: 3731-3737, 2007.